絞り込み

16641

広告

Denosumab in the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis.

著者 Yanbeiy ZA , Hansen KE
Drug Des Devel Ther.2019 ; 13():2843-2852.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (15view , 0users)

Full Text Sources

Glucocorticoid-induced osteoporosis (GIOP) is the most common form of secondary osteoporosis. In May 2018, denosumab was approved for the treatment of GIOP in men and women at high risk of fracture. We undertook a systematic review and meta-analysis to summarize the efficacy and safety of denosumab in the prevention and treatment of GIOP.
PMID: 31616133 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード